Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Metastatic Renal Cell Carcinoma (ORCHID)
NCT03786796Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jun 2019
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in renal cell carcinoma (RCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jun 2019; status: recruiting.
02
Drugs
olaparib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03786796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03786796.